Resum
Covalent inhibitors and other types of covalent modalities have seen a revival in the past two decades, with a variety of new targeted covalent drugs having been approved in recent years. A key feature of such molecules is an intrinsically reactive group, typically a weak electrophile, which enables the irreversible or reversible formation of a covalent bond with a specific amino acid of the target protein. This reactive group, often called the "warhead", is a critical determinant of the ligand's activity, selectivity, and general biological properties. In 2019, we summarized emerging and re-emerging warhead chemistries to target cysteine and other amino acids (; DOI: 10.1021/acs.jmedchem.8b01153). Since then, the field has rapidly evolved. Here we discuss the progress on covalent warheads made since our last Perspective and their application in medicinal chemistry and chemical biology.
| Idioma original | Anglès |
|---|---|
| Pàgines (de-a) | 7668-7758 |
| Nombre de pàgines | 91 |
| Revista | Journal of Medicinal Chemistry |
| Volum | 67 |
| Número | 10 |
| Data online anticipada | 7 de maig 2024 |
| DOIs | |
| Estat de la publicació | Publicada - 23 de maig 2024 |
| Publicat externament | Sí |
SDG de les Nacions Unides
Aquest resultat contribueix als següents objectius de desenvolupament sostenible.
-
ODS 3 Salut i benestar
Fingerprint
Navegar pels temes de recerca de 'Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update'. Junts formen un fingerprint únic.Com citar-ho
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver